Todd Bazemore - Oct 26, 2021 Form 4 Insider Report for Kala Pharmaceuticals, Inc. (KALA)

Role
CHIEF OPERATING OFFICER
Signature
/s/ Eric Trachtenberg, Attorney-in-Fact
Stock symbol
KALA
Transactions as of
Oct 26, 2021
Transactions value $
-$22,579
Form type
4
Date filed
10/28/2021, 08:03 PM
Previous filing
Jun 29, 2021
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALA Common Stock Sale -$22.6K -12.5K -9.32% $1.80* 122K Oct 26, 2021 Direct F1, F2, F3
holding KALA Common Stock 42 Oct 26, 2021 By son
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.89, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3 Includes 77,500 unvested RSUs.